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Available online 20 July 2016HIVDNA is amarker of HIV persistence that predicts HIV progression and remission, but its kinetics in early acute
HIV infection (AHI) is poorly understood. We longitudinally measured the frequency of peripheral blood mono-
nuclear cells harboring total and integrated HIV DNA in 19 untreated and 71 treated AHI participants, for whom
50were in the earliest Fiebig I/II (HIV IgM−) stage, that is ≤2 weeks from infection.Without antiretroviral ther-
apy (ART), HIV DNA peaked at 2 weeks after enrollment, reaching a set-point 2 weeks later with little change
thereafter. Therewas amarked divergence of HIV DNA values between the untreated and treated groups that oc-
curredwithin the ﬁrst 2weeks of ART and increasedwith time. ART reduced total HIV DNA levels by 20-fold after
2 weeks and 316-fold after 3 years. Therefore, very early ART offers the opportunity to signiﬁcantly reduce the
frequency of cells harboring HIV DNA.







HIV establishes reservoir within the human host early in infection,
rapidly replicating and seeding peripheral blood mononuclear cell
(PBMC) and tissue sanctuaries (Kulpa and Chomont, 2015). Frequencies
of PBMCs that harbor HIV DNA are higher in later stages of acute HIV in-
fection (AHI), suggesting that HIV reservoir seeding escalates with time
(Ananworanich et al., 2013, Cheret et al., 2015). HIV reservoir size is per-
tinent to the goal of HIV remission (i.e. undetectable plasma viral load
without treatment) because the size of the reservoir predicts time to
viral load rebound after ART cessation (Williams et al., 2014, Li et al.,ors and should not be construed
partment of Defense or other
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. This is an open access article under2016). It is hypothesized that people with a smaller reservoir size will
have a greater chance of achieving HIV remission (Ananworanich and
Fauci, 2015).
During early AHI, plasma viral RNA load rises exponentially and
reaches a peak of over 6 logs in just two weeks from when it is ﬁrst de-
tected in the blood, This is followed by a sharp decline in viremia to a
set-point level that is 2 logs lower 4 weeks later (Robb et al., 2016).
However, the kinetics of proviral DNA during early infection remains
largely unknown. The earlier treatment is initiated in AHI, the lower the
HIV reservoir size is after viral suppression (Ananworanich et al., 2012),
but the extent of reductions compared to no treatment in AHI is notwell
documented.
Here we leverage our ownwell-characterized untreated and treated
AHI cohorts to examine two questions: 1) what are the kinetics of peak
and set-point of total and integrated HIV DNA and 2-LTR circles in
PBMCs during untreated AHI? 2) what is the magnitude of difference
in reservoir size with andwithout ART during AHI? As proviral DNA de-
cays little in chronic HIV infection (Viard et al., 2004), identifying timing
of DNA set-point will inform when to intervene. The magnitude of res-
ervoir reduction may determine durability of HIV remission (Hill et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pared to no treatment will inform further interventions needed to
achieve durable HIV remission (Martin and Siliciano, 2016).
2. Materials and Methods
The RV217 cohort enrolled individuals at high risk for HIV in Pattaya,
Thailand who underwent twice-weekly HIV nucleic acid testing (NAT).
AnyNAT positive samplewas conﬁrmedwith quantitative HIV RNA and
serology (Robb et al., 2016). The 19 RV217 Thais were recruited from
July 2009 to January 2012 and selected as they were enrolled in Fiebig
stage I/II. Three additional Fiebig I/II participants were not included be-
cause they had insufﬁcient PBMCs for analysis. The RV254 study
(NCT00796146) enrolled individuals with non-reactive HIV IgG identi-
ﬁed through routine NAT and serology in Bangkok (De Souza et al.,
2015). Participants were offered immediate ART (NCT00796263). The
median (IQR) time from enrollment to ART initiation in RV254 was 2
(1 to 3) days. This analysis includes the ﬁrst 71 participants recruited
from April 2009 to November 2012.
Fiebig stages were categorized according to Fiebig and Busch (2):
Fiebig I/II: HIV RNA+, p24 antigen±, HIV IgM− and Fiebig III/IV: HIV
IgM+, Western Blot−/indeterminate. We estimated the duration
from the advent of viremia for each individual in our two cohorts
based on Fiebig et al. by assigning 10 days to those in Fiebig I/II and
14 days to those in Fiebig III/IV (Fiebig et al., 2003). Because RV254
had more Fiebig III/IV individuals than RV217, the estimated duration
since the advent of viremia is 4 days longer in RV254 (Table 1). To ac-
count for this time gap between the two cohorts, 4 days was added toTable 1








Age, mean (SD) 24 (4.9) 29 (7.1) 0.001
Gender, n (%) b0.001
Male 10 (53) 65 (92)
Female 1 (5) 6 (8)
Transgender 8 (42) –
Estimated duration from the
advent of viremia
Median (IQR) 10 (10−10) 14 (10–14) 0.001
Fiebig stage, n (%)
I–II (RNA+, p24 Ag±, HIV
IgM−)
17 (89) 33 (46) 0.001
III–IV (HIV IgM+, Western
Blot− or indeterminate)
2 (11) 38 (54)
HIV-subtype
CRF01_AE 17 (89.4) 59 (83.1) 0.34
B 1 (5.3) 3 (4.2)
CRF01_AE/B recombinant 1 (5.3) 7 (9.9)
Others – 2 (2.8)
CD4 T cells (cells/mm3), (n = 13)
Mean (SD) 1027 (296) 425 (198) b0.0001
Median (IQR) 993 (909–1193) 386 (293–532)
HIV RNA (log10copies/ml),
Mean (SD) 4.5 (2.0) 5.7 (1.1) 0.0007
Median (IQR) 4.1 (3.0–6.5) 5.7 (5.2–6.4)
Total HIV DNA (log10copies/106
PBMCs),
Mean (SD) 1.4 (1.5) 1.8 (1.3) 0.21




Mean (SD) 0.6 (1.1) 0.7 (1.0) 0.61
Median (IQR) 0 (0–0.8) 0 (0–1.7)
2-LTR circles
(log10copies/106PBMCs),
Mean (SD) 0.4 (0.7) 1.2 (1.0) 0.005
Median (IQR) 0 (0–0.9) 1.2 (0–1.9)
PBMCs: peripheral blood mononuclear cells.time fromenrollment on theX axis in RV254 in Figs. 1 to 3,which result-
ed in an alignment of the peak viremia and proviral DNA between the
two cohorts. Treatment in RV254 included 3-drug regimen (tenofovir,
lamivudine or emtricitabine, and efavirenz) with 40/71 participants re-
ceiving additional raltegravir and maraviroc during the ﬁrst 24 weeks
(Ananworanich et al., 2015). All relevant ethics committees approved
these studies and every participant provided informed consent. Samples
and data were de-identiﬁed for analyses.
Total and integratedHIVDNAweremeasured in triplicates in PBMCs
using amodiﬁednested PCR assay for CRF01_AEandB (Vandergeeten et
al., 2014), and the levelswere log10 transformed prior to analysis. Differ-
ences between groups were assessed using two-tailed Student's t-test.
Generalized Estimating Equationswere used to assess factors associated
with proviral burden. The model was constructed using an exchange-
able correlation matrix. Analyses were performed using StataCorp
2013 (StataCorp LP, College Station, TX). Figures were generated with
Prism version 6.02 for Windows (GraphPad Software, La Jolla, CA).
3. Results
The RV217 untreated cohort started sampling at amedian (IQR) of 1
(1–7) day from the ﬁrst documented HIV RNA in the study (median of
13,183 copies/ml). The RV254 treated participants enrolled at a median
(IQR) of 16 (12−21) days from the history of HIV exposure.
Themajority were Men who have Sex withMen. The most common
HIV clade was CRF01_AE. RV217 participants were younger, included
transgender women and more were in Fiebig I/II; the latter resulted in
shorter estimated duration from the advent of viremia, higher CD4
count and lower HIV RNA compared to the RV254 cohort. However,
baseline total and integrated HIV DNA values were similar between
groups.
The plasma HIV RNA kinetics in Fig. 1 illustrates the peak viremia at
week 2 and set-point at week 4 from enrollment in the untreated group.
In contrast, viremia declined rapidly after treatment initiation in RV254,
and the proportionswith HIV RNA b 50 copies/mlwere 90% at week 24,
99% at week 48 and 97% at week 144.
The frequencies of PBMCs harboring total HIV DNA are shown in
Fig. 2, which illustrates 3 important points 1) In the untreated RV217 co-
hort, the total HIV DNA values rose rapidly in the ﬁrst 2 weeks after en-
rollmentwithout signiﬁcant changes thereafter. 2) In the RV254 treated
cohort, the total HIV DNA values decreased over time reaching very low
levels at week 144. 3) There was a marked divergence of total HIV DNA
values between the untreated and treated cohorts that occurred early
and this increased with time (Table 2).
The differences were 1.3 log or 20-fold at week 2 following enroll-
ment, and 2.5 log or 316-fold by week 144. The integrated DNA values
rose rapidly and peaked at week 2 followed by a signiﬁcant decline at
week 4 after which there was a gradual increase in integrated HIV
DNA resulting in signiﬁcantly higher integrated HIV DNA at week 144Fig. 1. Plasma HIV RNA of RV217 untreated and RV254 treated acute HIV infection
participants. Footnote: The detection limit of HIV RNAwas either 1.7 or 1.3 log10copies/ml.
Fig. 2. Total and integrated HIV DNA and 2-LTR circles in peripheral blood mononuclear
cells of Fiebig I to IV RV217 untreated and RV254 treated acute HIV infection
participants. Footnote: PBMCs: peripheral blood mononuclear cells.
70 J. Ananworanich et al. / EBioMedicine 11 (2016) 68–72compared to week 4 (p = 0.02) (Fig. 2). By week 2, the treated cohort
had 1.4 log or 25-fold lower integrated HIV DNA and by week 144, the
difference was 2 log or 100-fold (Table 2). When only participants at
the earliest AHI stages of Fiebig I/II were included (17 in RV217 and
33 in RV254), similarﬁndings for total and integratedHIVDNAwere ob-
served as compared to the whole group (Fig. 3).
The frequency of cells harboring 2-LTR circles at baselinewas higher
in the RV254 group (Fig. 2 and Table 1) likely because of lower propor-
tions of Fiebig I/II individuals in RV254 than in RV217. The baseline
levels of 2-LTR circles did not differ between cohorts if only the Fiebig
I/II participants were included: mean (SD) 0.7 (0.8) in RV254 vs. 0.4
(0.7) in RV217, p = 0.19 (Fig. 3). The levels subsequently declined sig-
niﬁcantly after 48weeks of ART (p b 0.0001), whereas, in the untreated
individuals, 2-LTR circles rose quickly betweenweek 0 andweek 2 (p=
0.006) and remained high throughout the follow up period (Fig. 2, Fig. 3
and Table 2).
As CD4+ T cell values differ signiﬁcantly over time between the un-
treated vs. the treated groups, we also calculated the frequencies of
CD4+T cells that harbor total and integratedHIVDNA and 2-LTR circles
using information of frequencies of CD4+ T cells from complete blood
count (Supplemental Table 1). This resulted in greater differences be-
tween the treated and untreated cohorts with a 1585-fold difference
in total HIV DNA and 501-fold difference in integrated HIV DNA ob-
served at week 144.
Two baseline factors were strongly associated with total HIV DNA at
week 144 in the multivariate analysis: Total HIV DNA (coeff 0.50, 95%CI
0.44 to 0.57, p b 0.001) and ART (coeff−1.39, 95%CI−1.14 to−1.64,
p b 0.001). Similar relationships were observed for integrated HIV
DNA at week 144: baseline integrated HIV DNA (coeff 0.57, 95%CI 0.47
to 0.68, p b 0.001) and ART (coeff −1.20, 95%CI −0.91 to −1.48,
p b 0.001). HIV DNA outcomes did not differ for the 3- vs. 5-drug regi-
mens. In the RV217 cohort, peak HIV RNA did not correlate with totalFig. 3. Total and integrated HIV DNA and 2-LTR circles in peripheral blood mononuclear
cells of Fiebig I/II RV217 untreated and RV254 treated acute HIV infection participants.HIV DNA at set-point (week 4) (r = 0.17, p = 0.55) or at week 48
(r = 0.11, p = 0.68).
4. Discussion
This study compares proviral DNA in the earliest stages of AHI be-
tween untreated vs. treated individuals in two cohorts with similar gen-
der, ethnicity, setting, HIV subtype and baseline total and integratedHIV
DNA values, and with the same HIV DNA quantiﬁcation methods
(Vandergeeten et al., 2014). In the RV217 untreated cohort, the HIV
DNA measurements performed within 4 to 6 weeks following the ad-
vent of viremia determined the reservoir size in the chronic stage.
Therefore, the “HIV DNA set-point” is established very early and at the
time of plasma HIV RNA set-point, at the conclusion of acute viremia
(Robb et al., 2016). Stark differences in HIV DNA levels were observed
between the treated and untreated cohorts, with a 20-fold lower total
HIV DNA after 2 weeks of ART. As HIV DNA continues to decline in the
treated group, it remains high in the untreated cohort, resulting in a
300-fold difference in total HIV DNA and a 100-fold difference in inte-
grated HIV DNA after 3 years. Others have shown a marked decline in
HIV DNA when ART was initiated by 15 days following infection but
not later (Laanani et al., 2015). Continued HIV DNA reduction during
long-term ART is observed when ART was initiated early (Buzon et al.,
2014).
The rapidly-established pool of cells harboringHIVDNA in untreated
AHI shows little decay over time (Cone et al., 1998) andmay have long-
term consequences. Indeed, HIV DNA levels before ART are correlated
with post-treatment HIV DNA levels, residual viremia and immune acti-
vation (Groves et al., 2012, Jain et al., 2013). Higher HIV DNA also pre-
dicts HIV disease progression, independent of HIV RNA and CD4 count
(Goujard et al., 2006, Rouzioux et al., 2005). Pre-treatment total HIV
DNA predicted time to viral rebound when ART was interrupted
(Williams et al., 2014), and post-treatment controllers maintained low
HIV DNA after treatment interruption (Saez-Cirion et al., 2013). Gener-
ally reducing the frequencies of cells harboring HIV DNAwith early ART
may be critical in the efforts towards HIV remission. It must be noted,
however, that failure to detect HIV DNA does not necessarily result in
durable HIV remission. This was clearly exempliﬁed in the Boston pa-
tients and the Mississippi child who had no detectable HIV DNA or
other markers of active HIV reservoirs, they subsequently experienced
resurgence of viremia when ART was removed (Henrich et al., 2014,
Persaud and Luzuriaga, 2014). The best measures of HIV reservoirs
that could predict HIV remission remain unknown (Siliciano and
Siliciano, 2014, Eriksson et al., 2013). Additionally, the bulk of the HIV
reservoirs may be in tissues particularly the lymph nodes
(Lorenzo-Redondo et al., 2016, Rothenberger et al., 2015), which are
more difﬁcult to collect and often not measured in studies.
The lower plasma HIV RNA levels and frequencies of cells harboring
2-LTR circles at enrollment in RV217 were likely because of the higher
proportion of people in the FIebig I/II stages (89% vs. 46% in RV254).
Similar to plasma viremia, both total and integrated DNA peaked early
at week 2 after enrollment in untreated AHI. The total HIV DNA showed
a trend towards decay between weeks 2 and 4 from enrollment while
this decline was signiﬁcant for integrated HIV DNA. This could be from
the preferential killing of productively infected cells during early AHI,
as these cells harbor integrated HIV DNA (Laanani et al., 2015).
Prolonged stable ART initiated in AHI resulted in a small frequency of
cells harboring HIV DNA, mainly in its integrated form. In untreated in-
fection, ongoing viral production continues, and both integrated HIV
DNA and non-integrated HIV DNA accumulate, consistent with our
data (Vandergeeten et al., 2014). Association with replication compe-
tent HIV appears stronger for integrated than total HIV DNA in the
acutely treated (Eriksson et al., 2013) but the reverse is observed in
chronically treated individuals (Kiselinova et al., 2016, Eriksson et al.,
2013), which may be due to the high burden of mostly defective, non-
integrated forms of DNA in the latter group (Vandergeeten et al., 2014).
Table 2
Differences in frequencies of peripheral blood mononuclear cells harboring total and integrated HIV DNA and 2-LTR circles between the RV217 untreated and RV254 treated acute HIV
infection cohorts.
RV217 untreated RV254 treated Mean log difference 95%CI (RV254-RV217) p Fold difference
n Mean (SD) n Mean (SD)
Total HIV DNA (log10copies/106PBMCs)
Enrollment 19 1.4 (1.5) 71 1.8 (1.3) 0.4 (-0.2 to 1.1) 0.21 2.5
Week 2 12 3 (0.4) 69 1.6 (1.1) −1.3 (−0.7 to−2.0) 0.0001 20
Week 48 17 2.7 (0.5) 70 1 (0.9) −1.7 (−1.3 to−2.2) b0.0001 50
Week 144 10 3 (0.6) 62 0.4 (0.7) −2.5 (−2.1 to−3.0) b0.0001 316
Integrated HIV DNA (log10copies/106PBMCs)
Enrollment 19 0.6 (1.1) 69 0.7 (1) 0.1 (−0.4 to 0.7) 0.61 1.3
Week 2 12 1.9 (0.5) 67 0.5 (0.8) −1.4 (−1.0 to−1.9) b0.0001 25
Week 48 17 1.7 (0.8) 69 0.1 (0.4) −1.5 (−1.3 to−1.8) b0.0001 32
Week 144 10 2.2 (0.6) 62 0.2 (0.5) −2.0 (−1.7 to−2.3) b0.0001 100
2-LTR circles (log10copies/106PBMCs)
Enrollment 17 0.4 (0.7) 70 1.2 (1.0) 0.8 (0.2 to 1.3) 0.005 6.3
Week 2 12 1.3 (0.8) 68 1.2 (1.1) −0.1 (−0.7 to 0.6) 0.9 1.3
Week 48 16 1.5 (0.7) 66 0.6 (0.8) −0.9 (-0.5 to -1.3) 0.0001 8
Week 144 9 1.5 (0.6) ND ND ND NA NA
PBMCs: peripheral blood mononuclear cells, ND: not done, NA: not applicable.
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expressed reservoir markers (e.g. cell-associated HIV RNA), replication
competent virus and tissue reservoirs that are relevant to HIV remission
(Li et al., 2016). The longitudinal reservoir assessment in 50 Fiebig I/II is
amajor strength compared to past studies (Groves et al., 2012, Jain et al.,
2013,Williams et al., 2014). Finally, the consequences of a small HIV res-
ervoir size from early ART on clinical outcomes are not well understood.
In conclusion, theHIVDNA set-point is established early in AHI. Over
three years without ART, persons with AHI carry a frequency of infected
cells that is 300-fold higher than those on ART. As there are no strategies
that could markedly reduce proviral burden, the opportunity to alter
HIV DNA levels is with very early ART.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.07.024.
Funding Sources
This work was supported by cooperative agreements (W81XWH-
07-2-0067,W81XWH-11-2-0174) between theHenryM. Jackson Foun-
dation for the Advancement of Military Medicine, and the U.S. Depart-
ment of the Army and by an intramural grant from the Thai Red Cross
AIDS Research Center. The Government Pharmaceutical Organization
(GPO), Thailand, Gilead, Merck and ViiV Healthcare provided support
for antiretroviral medications. JA was partially funded by NIAID
R01AI114236.
Role of the Funders
The funders had no role in preparing this manuscript.
Conﬂict of Interest Statement
JA has received honoraria fromViiVHealthcare andMerck. Other au-
thors declare no conﬂict of interest.
Author Contributions
JA andMLR designed and led the two clinical cohorts with input and
contribution from EK, JLKF, ST, RC, NM and NP. NC, ST, MB, CV and MN
designed and performed the reservoir testing. SP planned and conduct-
ed the statistical analysis. JA prepared the ﬁrst draft of the manuscript
and all authors contributed in the ﬁnalization of the work.Acknowledgements
We thank our study participants and staff from the Thai Red Cross
AIDS Research Centre, Chulalongkorn University and AFRIMS for their
valuable contributions to this study.
The RV217 and RV254/SEARCH 010 Study Groups include from
SEARCH/TRCARC/HIV-NAT: Praphan Phanuphak, Nipat Teeratakulpisarn,
Supanit Pattanachaiwit, Thep Chalermchai, Donn Colby, Duanghathai
Sutthichom, Somprartthana Rattanamanee, Peeriya Prueksakaew,
Sasiwimol Ubolyam, Pacharin Eamyoung, Naphassanant Laopraynak,
Suwanna Puttamaswin, Nitiya Chomchey and Putthachard Karnsomlap;
from AFRIMS: Sorachai Nitayaphan, Somchai Sriplienchan, Rapee
Trichavaroj, Alexandra Schuetz, Nicos Karasavvas, Sandhya Vasan,
Yuwadee Phuang-Ngern, Surt Jongrakthaitae, Werrawan Chuenaron,
Rapee Trichavaroj, Nantana Tantibul, Hathairat Savadsuk, Kirsten Smith,
TanyaWansom, Siriwat Akapirat, Robert J. O'Connell, Bessara Nuntapinit;
from MHRP: Trevor Crowell, Madelaine Ouellette, Oratai Butterworth,
Linda L. Jagodzinski, Jennifer Malia, Mark Manak, Eric Sanders-Buell,
Morgane Rolland, Julie Dorsey-Spitz, Michael A. Eller, Mark Milazzo,
Qun Li, Sheila Peel, Jerome H. Kim; from University of Montreal: Remi
Fromentin; from former VGTI-Florida: Claire Vandergeeten, Wendy
Bakeman, Lydie Trautmann, Raﬁck Sekaly.
References
Ananworanich, J., Fauci, A.S., 2015. HIV cure research: a formidable challenge. J. Virus
Erad. 1, 1–3.
Ananworanich, J., Schuetz, A., Vandergeeten, C., Sereti, I., De Souza, M., Rerknimitr, R.,
Dewar, R., Marovich, M., van Griensven, F., Sekaly, R., Pinyakorn, S., Phanuphak, N.,
Trichavaroj, R., Rutvisuttinunt, W., Chomchey, N., Paris, R., Peel, S., Valcour, V.,
Maldarelli, F., Chomont, N., Michael, N., Phanuphak, P., Kim, J.H., Group, R. S. S.,
2012. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and
HIV reservoir seeding during acute HIV infection. PLoS One 7, e33948.
Ananworanich, J., Fletcher, J.L., Pinyakorn, S., van Griensven, F., Vandergeeten, C., Schuetz,
A., Pankam, T., Trichavaroj, R., Akapirat, S., Chomchey, N., Phanuphak, P., Chomont, N.,
Michael, N.L., Kim, J.H., de Souza, M., Group, R. S. S., 2013. A novel acute HIV infection
staging system based on 4th generation immunoassay. Retrovirology 10, 56.
Ananworanich, J., Chomont, N., Fletcher, J.L., Pinyakorn, S., Schuetz, A., Sereti, I.,
Rerknimitr, R., Dewar, R., Kroon, E., Vandergeeten, C., Trichavaroj, R., Chomchey, N.,
Chalermchai, T., Michael, N.L., KIM, J.H., Phanuphak, P., Phanuphak, N., 2015. Markers
of HIV reservoir size and immune activation after treatment in acute HIV infection
with and without raltegravir and maraviroc intensiﬁcation. J. Virus Erad. 1, 116–122.
Buzon, M.J., Martin-Gayo, E., Pereyra, F., Ouyang, Z., Sun, H., Li, J.Z., Piovoso, M., Shaw, A.,
Dalmau, J., Zangger, N., Martinez-Picado, J., Zurakowski, R., Yu, X.G., Telenti, A.,
Walker, B.D., Rosenberg, E.S., Lichterfeld, M., 2014. Long-term antiretroviral treat-
ment initiated at primary HIV-1 infection affects the size, composition, and decay ki-
netics of the reservoir of HIV-1-infected CD4 T cells. J. Virol. 88, 10056–10065.
Cheret, A., Bacchus-Souffan, C., Avettand-Fenoel, V., Melard, A., Nembot, G., Blanc, C.,
Samri, A., Saez-Cirion, A., Hocqueloux, L., Lascoux-Combe, C., Allavena, C., Goujard,
C., Valantin, M.A., Leplatois, A., Meyer, L., Rouzioux, C., Autran, B., GROUP, O. A.-S.,
72 J. Ananworanich et al. / EBioMedicine 11 (2016) 68–722015. Combined ART started during acute HIV infection protects central memory
CD4+ T cells and can induce remission. J. Antimicrob. Chemother. 70, 2108–2120.
Cone, R.W., Gowland, P., Opravil, M., Grob, P., Ledergerber, B., 1998. Levels of HIV-infected
peripheral blood cells remain stable throughout the natural history of HIV-1 infec-
tion. Swiss HIV Cohort Study. AIDS 12, 2253–2260.
de Souza, M.S., Phanuphak, N., Pinyakorn, S., Trichavaroj, R., Pattanachaiwit, S., Chomchey,
N., Fletcher, J.L., Kroon, E.D., Michael, N.L., Phanuphak, P., Kim, J.H., Ananworanich, J.,
Group, R. S. S., 2015. Impact of nucleic acid testing relative to antigen/antibody com-
bination immunoassay on the detection of acute HIV infection. AIDS 29, 793–800.
Eriksson, S., Graf, E.H., Dahl, V., Strain, M.C., Yukl, S.A., Lysenko, E.S., Bosch, R.J., Lai, J.,
Chioma, S., Emad, F., Abdel-Mohsen, M., Hoh, R., Hecht, F., Hunt, P., Somsouk, M.,
Wong, J., Johnston, R., Siliciano, R.F., Richman, D.D., O'Doherty, U., Palmer, S., Deeks,
S.G., Siliciano, J.D., 2013. Comparative analysis of measures of viral reservoirs in
HIV-1 eradication studies. PLoS Pathog. 9, e1003174.
Fiebig, E.W., Wright, D.J., Rawal, B.D., Garrett, P.E., Schumacher, R.T., Peddada, L.,
Heldebrant, C., Smith, R., Conrad, A., Kleinman, S.H., Busch, M.P., 2003. Dynamics of
HIV viremia and antibody seroconversion in plasma donors: implications for diagno-
sis and staging of primary HIV infection. AIDS 17, 1871–1879.
Goujard, C., Bonarek, M., Meyer, L., Bonnet, F., Chaix, M.L., Deveau, C., Sinet, M., Galimand,
J., Delfraissy, J.F., Venet, A., Rouzioux, C., Morlat, P., Agence Nationale de Recherche sur
le Sida, P. S. G., 2006. CD4 cell count and HIV DNA level are independent predictors of
disease progression after primary HIV type 1 infection in untreated patients. Clin. In-
fect. Dis. 42, 709–715.
Groves, K.C., Bibby, D.F., Clark, D.A., Isaksen, A., Deayton, J.R., Anderson, J., Orkin, C., Stagg,
A.J., Mcknight, A., 2012. Disease progression in HIV-1-infected viremic controllers.
J. Acquir. Immune Deﬁc. Syndr. 61, 407–416.
Henrich, T.J., Hanhauser, E., Marty, F.M., Sirignano, M.N., Keating, S., Lee, T.H., Robles, Y.P.,
Davis, B.T., Li, J.Z., Heisey, A., Hill, A.L., Busch, M.P., Armand, P., Soiffer, R.J., Altfeld, M.,
Kuritzkes, D.R., 2014. Antiretroviral-free HIV-1 remission and viral rebound after allo-
geneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161, 319–327.
Hill, A.L., Rosenbloom, D.I., Fu, F., Nowak, M.A., Siliciano, R.F., 2014. Predicting the out-
comes of treatment to eradicate the latent reservoir for HIV-1. Proc. Natl. Acad. Sci.
U. S. A. 111, 13475–13480.
Jain, V., Hartogensis, W., Bacchetti, P., Hunt, P.W., Hatano, H., Sinclair, E., Epling, L., Lee,
T.H., Busch, M.P., Mccune, J.M., Pilcher, C.D., Hecht, F.M., Deeks, S.G., 2013. Antiretro-
viral therapy initiated within 6 months of HIV infection is associated with lower T-
cell activation and smaller HIV reservoir size. J. Infect. Dis. 208, 1202–1211.
Kiselinova, M., de Spiegelaere, W., Buzon, M.J., Malatinkova, E., Lichterfeld, M.,
Vandekerckhove, L., 2016. Integrated and Total HIV-1 DNA predict ex vivo viral out-
growth. PLoS Pathog. 12, e1005472.
Kulpa, D.A., Chomont, N., 2015. HIV persistence in the setting of antiretroviral therapy:
when, where and how does HIV hide? J. Virus Erad. 1, 59–66.
Laanani, M., Ghosn, J., Essat, A., Melard, A., Seng, R., Gousset, M., PANJO, H., Mortier, E.,
Girard, P.M., Goujard, C., Meyer, L., Rouzioux, C., Agence Nationale de Recherche sur
le SIDA, P. C. S. G., 2015. Impact of the timing of initiation of antiretroviral therapy
during primary HIV-1 infection on the decay of cell-associated HIV-DNA. Clin. Infect.
Dis. 60, 1715–1721.
Li, J.Z., Etemad, B., Ahmed, H., Aga, E., Bosch, R.J., Mellors, J.W., Kuritzkes, D.R., Lederman,
M.M., Para, M., Gandhi, R.T., 2016. The size of the expressed HIV reservoir predicts
timing of viral rebound after treatment interruption. AIDS 30, 343–353.Lorenzo-Redondo, R., Fryer, H.R., Bedford, T., Kim, E.Y., Archer, J., Kosakovsky Pond, S.L.,
Chung, Y.S., Penugonda, S., Chipman, J.G., Fletcher, C.V., Schacker, T.W., Malim, M.H.,
Rambaut, A., Haase, A.T., Mclean, A.R., Wolinsky, S.M., 2016. Persistent HIV-1 replica-
tion maintains the tissue reservoir during therapy. Nature 530, 51–56.
Martin, A.R., Siliciano, R.F., 2016. Progress toward HIV eradication: case reports, current
efforts, and the challenges associated with cure. Annu. Rev. Med. 67, 215–228.
Persaud, D., Luzuriaga, K., 2014. Absence of HIV-1 after treatment cessation in an infant. N.
Engl. J. Med. 370, 678.
Robb, M.L., Eller, L.A., Kibuuka, H., Rono, K., Maganga, L., Nitayaphan, S., Kroon, E., Sawe,
F.K., Sinei, S., Sriplienchan, S., Jagodzinski, L.L., Malia, J., Manak, M., de Souza, M.S.,
Tovanabutra, S., Sanders-Buell, E., Rolland, M., Dorsey-Spitz, J., Eller, M.A., Milazzo,
M., LI, Q., Lewandowski, A., Wu, H., Swann, E., O'Connell, R.J., Peel, S., Dawson, P.,
Kim, J.H., Michael, N.L., Team, R. V. S., 2016. Prospective study of acute HIV-1 infection
in adults in East Africa and Thailand. N. Engl. J. Med. 374, 2120–2130.
Rothenberger, M.K., Keele, B.F., Wietgrefe, S.W., Fletcher, C.V., Beilman, G.J., Chipman, J.G.,
Khoruts, A., Estes, J.D., Anderson, J., Callisto, S.P., Schmidt, T.E., Thorkelson, A., Reilly,
C., Perkey, K., Reimann, T.G., Utay, N.S., Nganou Makamdop, K., Stevenson, M.,
Douek, D.C., Haase, A.T., Schacker, T.W., 2015. Large number of rebounding/founder
HIV variants emerge frommultifocal infection in lymphatic tissues after treatment in-
terruption. Proc. Natl. Acad. Sci. U. S. A. 112, E1126–E1134.
Rouzioux, C., Hubert, J.B., Burgard, M., Deveau, C., Goujard, C., Bary, M., Sereni, D., Viard,
J.P., Delfraissy, J.F., Meyer, L., GROUP, S. C. S., 2005. Early levels of HIV-1 DNA in pe-
ripheral blood mononuclear cells are predictive of disease progression independently
of HIV-1 RNA levels and CD4+ T cell counts. J. Infect. Dis. 192, 46–55.
Saez-Cirion, A., Bacchus, C., Hocqueloux, L., Avettand-Fenoel, V., Girault, I., Lecuroux, C.,
Potard, V., Versmisse, P., Melard, A., Prazuck, T., Descours, B., Guergnon, J., Viard,
J.P., Boufassa, F., Lambotte, O., Goujard, C., Meyer, L., Costagliola, D., Venet, A.,
Pancino, G., Autran, B., Rouzioux, C., Group, A. V. S., 2013. Post-treatment HIV-1 con-
trollers with a long-term virological remission after the interruption of early initiated
antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 9, e1003211.
Siliciano, J.D., Siliciano, R.F., 2014. Recent developments in the search for a cure for HIV-1
infection: targeting the latent reservoir for HIV-1. J. Allergy Clin. Immunol. 134,
12–19.
Vandergeeten, C., Fromentin, R., Merlini, E., Lawani, M.B., Dafonseca, S., Bakeman, W.,
McNulty, A., Ramgopal, M., Michael, N., KIM, J.H., Ananworanich, J., Chomont, N.,
2014. Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in
large-cohort studies. J. Virol. 88, 12385–12396.
Viard, J.P., Burgard, M., Hubert, J.B., Aaron, L., Rabian, C., Pertuiset, N., Lourenco, M.,
Rothschild, C., Rouzioux, C., 2004. Impact of 5 years of maximally successful highly ac-
tive antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 18, 45–49.
Williams, J.P., Hurst, J., Stohr, W., Robinson, N., Brown, H., Fisher, M., Kinloch, S., Cooper,
D., Schechter, M., Tambussi, G., Fidler, S., Carrington, M., Babiker, A., Weber, J.,
Koelsch, K.K., Kelleher, A.D., Phillips, R.E., Frater, J., Investigators, S. P., 2014. HIV-1
DNA predicts disease progression and post-treatment virological control. Elife 3,
e03821.
